AI-generated summary
The authors describe a protocol for a planned double-blind randomised trial comparing photobiomodulation at 660 nm with clobetasol propionate 0.05% for oral lichen planus. Forty-four patients are to be randomised into two groups of 22, with pain as the primary outcome. The abstract reports no results, since this is a study protocol.
- Participants
- 44
- Who or what was studied
- Patients with symptomatic and histopathologically diagnosed oral lichen planus
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract describes a study protocol only, so no efficacy findings are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmjopen.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Energy density (fluence)
- 177 J/cm2
- Power
- 100 mW
- Total energy
- 0.5J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Anxiety, Depression, Visual analogue scale, Trial registration, Control group, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.